Objective:

The objective of this study was to directly compare the probability of healing with Vonoprazan and Esomeprazol in the treatment of erosive esophagitis associated with gastroesophageal reflux disease, evaluating both symptom resolution and endoscopic healing.

Methodology:

A prospective observational study was conducted with 60 patients aged 18 to 75, divided into two groups of 30. One group received Vonoprazan 20 mg twice daily (BID) and the other Esomeprazol 20 mg BID for 8 weeks. Endoscopies were performed at baseline and at the end of treatment, and daily records of heartburn and regurgitation were collected.

Results:

Vonoprazan showed higher endoscopic healing rates across all severity grades (A D, Los Angeles Classification). In Grade D, Vonoprazan achieved a 50% healing rate, while Esomeprazol did not resolve any cases. Symptom relief: Vonoprazan led to complete disappearance of symptoms from day 2 through week 8 in all patients. In contrast, mild symptoms persisted in some Esomeprazol patients until the end of follow-up. No relevant adverse effects were reported.

Conclusion:

Vonoprazan is superior to Esomeprazol in endoscopic healing and in achieving faster and more sustained symptom control in the treatment of EE.